Mechanism of action
The hypothalamus in the brain makes growth hormone-releasing hormone (GHRH). GHRH tells the pituitary gland to release growth hormone, which then raises levels of another hormone, IGF-1. Sermorelin copies the active part of GHRH. It works upstream of growth hormone, so the body still controls how much growth hormone the pituitary releases.
History and approval
Sermorelin was sold in the US under the brand name Geref by Serono (later EMD Serono). The FDA approved a diagnostic form on December 28, 1990, used to test whether the pituitary can release growth hormone. On September 26, 1997, the FDA approved Geref injection for treating idiopathic growth hormone deficiency in children with growth failure.
EMD Serono stopped making both Geref products in 2008, and the FDA withdrew the approvals effective June 18, 2009. In a 2013 notice in the Federal Register, the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness.
Availability today
There is no FDA-approved sermorelin product on the US market today. Sermorelin is prepared by state-licensed compounding pharmacies, including 503A pharmacies, for an individual prescription. Compounded sermorelin is not an FDA-approved product, so the FDA has not reviewed it for safety, effectiveness or quality.
Some clinics and telehealth programs prescribe compounded sermorelin to adults, often as an injection under the skin. These uses in adults are outside the original Geref labeling. To compare online programs, see our sermorelin provider comparison.
Side effects
In studies of the approved Geref product in children, sermorelin was generally well tolerated. The most common side effects reported were short-lived facial flushing and pain at the injection site. A prescriber reviews a person's health history before prescribing sermorelin.
See also
References
- Prakash A, Goa KL, "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency", BioDrugs 1999. pubmed.ncbi.nlm.nih.gov
- Federal Register, 78 FR 14095, Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness (March 4, 2013). federalregister.gov
- Drugs@FDA, Geref (NDA 020443). accessdata.fda.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.